# US 2021/0196737 A1 · Use of trezastilbenoside in manufacture of product for treating and/or preventing non-alcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196737 A1
- Document ID: US20210196737A1
- Status: Published application
- Kind: A1
- Application number: 17/137,311
- Filed: 2020-12-29
- Published: 2021-07-01
- Earliest claimed: 2019-12-30
- Assignees: Kpc Pharmaceuticals, Inc.
- Applicants: Kpc Pharmaceuticals, Inc.
- Inventors: Yidan LIU; Junfeng LIU; Xujuan YANG; Xi HUANG; Qing HUANG; Ke MENG; Guoguang LIU; Jianhua SHANG
- Web page: https://patentgrep.com/patent/US20210196737A1

## CPC

- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention belongs to the technical field of biopharmaceuticals, and discloses the application of Trezastilbenoside in the manufacture of products for treating and/or preventing non-alcoholic fatty liver disease. The research of the present invention shows that after giving Trezastilbenoside to non-alcoholic fatty liver disease (NAFLD) model mice for 4 consecutive weeks, the serum TC, TG, and LDL content were all significantly reduced, and the HDL content was significantly increased, indicating that the drug has a lipid regulatory effect. The activities of AST and ALT in the serum were significantly weakened, and the infiltration of inflammatory factors in the liver tissue was reduced, indicating that the drug has a hepatoprotective effect. It can not only reduce the fat content of the liver, but also improve the pathological form of fatty liver, indicating an effect of against NASH.

## Claims

### Claim 1

A method of treating and/or preventing non-alcoholic fatty liver disease, comprising administering Trezastilbenoside to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering Trezastilbenoside to the subject to improve the increase in body weight and/or liver weight of the subject.

### Claim 3 (depends on 1)

The method of claim 1, comprising administering Trezastilbenoside to the subject to improve the increase in total cholesterol and/or triglycerides in serum of the subject.

### Claim 4 (depends on 1)

The method of claim 1, comprising administering Trezastilbenoside to the subject to improve the increase in low density lipoprotein in serum of the subject.

### Claim 5 (depends on 1)

The method of claim 1, comprising administering Trezastilbenoside to the subject to improve the increase in aspartate aminotransferase and/or alanine aminotransferase in serum of the subject.

### Claim 6 (depends on 1)

The method of claim 1, comprising administering Trezastilbenoside to the subject to improve the decrease in high density lipoprotein in serum of the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the product includes a food product, a health product and a medicament.

### Claim 8 (depends on 1)

The method of claim 1, wherein the product for treating and/or preventing non-alcoholic fatty liver disease is a medicament, comprising Trezastilbenoside and a pharmaceutically acceptable adjuvant.

### Claim 9 (depends on 8)

The method of claim 8, wherein the medicament for treating and/or preventing non-alcoholic fatty liver disease is provided as various acceptable dosage forms;
preferably, the dosage forms include injections, tablets, capsules, powders, pills or oral solutions.

### Claim 10

A product for treating and/or preventing non-alcoholic fatty liver disease, comprising Trezastilbenoside;
preferably, the product includes a food product, a health product and a medicament; and
preferably, the product is a medicament comprising Trezastilbenoside and a pharmaceutically acceptable adjuvant.
